Company News: Page (1) of 1 - 05/16/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018

(May 16, 2018)

First analysis from Phase 3 CheckMate -227 Part 1b in first-line non-small cell lung cancer, assessing Opdivo plus chemotherapy and Opdivo plus Yervoy versus chemotherapy in patients with PD-L1 <1%

Updated data from Phase 3 CheckMate -238 study of Opdivo as adjuvant treatment in Stage III/IV melanoma will further explore potential durability of recurrence-free survival

Seven BMS compounds to be featured in presentations spanning more than 20 types of cancer

PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #ASCO18--Bristol-Myers Squibb Company (NYSE:BMY) today announced that data from over 70 Company-sponsored studies and collaborations evaluating its oncology compounds across more than 20 types of cancer will be featured at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 in Chicago from June 1-5. Presentations will report data from clinical trials highlighting the potential role of Immuno-Oncology (I-O)–based combinations, including translational research to help identify patient populations that may have the potential to benefit from I-O therapy. Additional findings include patient-reported outcomes and real-world data.




Key data from Company-sponsored studies and supported research include:

Bristol-Myers Squibb Oral Abstracts

  • Nivolumab plus platinum-doublet chemotherapy vs chemo as first-line treatment for advanced non-small cell lung cancer with <1% tumor PD-L1 expression: results from CheckMate -227
    Author: H. Borghaei
    Abstract #9001
    Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic
    Monday, June 4, 3:12-3:24 PM CDT, Hall B1
  • NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary Phase 1/2 results of PIVOT
    Author: A. Diab
    Abstract #3006
    Oral Abstract Session: Developmental Therapeutics—Immunotherapy
    Saturday, June 2, 5-5:12 PM CDT, Hall B1
  • Adjuvant therapy with nivolumab vs ipilimumab after complete resection of stage III/IV melanoma: Updated results from a Phase 3 trial (CheckMate -238)
    Author: J. Weber
    Abstract #9502
    Oral Abstract Session: Melanoma/Skin Cancers
    Monday, June 4, 8:24-8:36 AM CDT, Arie Crown Theater
  • Nivolumab as neoadjuvant therapy in patients with resectable Merkel cell carcinoma in CheckMate -358
    Author: S. Topalian
    Abstract #9505
    Oral Abstract Session: Melanoma/Skin Cancers
    Monday, June 4, 9:48-10 AM CDT, Arie Crown Theater
  • Adaptive Phase 2 randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data
    Author: M. Kok
    Abstract #1012
    Clinical Science Symposium Session: Breast Cancer Immunotherapy: Can we Crack the Code?
    Monday June 4, 3:48-4 PM CDT, Hall D2

New / Early Assets and Translational Medicine

  • BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab: Updated safety across all tumor cohorts and efficacy in patients with advanced bladder cancer
    Author: J. Tabernero
    Abstract #4512
    Poster Discussion Session: Genitourinary (Nonprostate) Cancer
    Saturday, June 2, 8-11:30 AM CDT, Hall A, Poster Board #338
    Discussed at the Poster Discussion Session on Saturday, June 2, 1:15-2:30 PM CDT, Hall D2
  • Phase 1 trial of BMS-986253, an anti-IL-8 monoclonal antibody in patients with metastatic or unresectable solid tumors
    Author: J. Collins
    Abstract #3091
    Poster Session: Developmental Therapeutics—Immunotherapy
    Monday, June 4, 8-11:30 AM CDT, Hall A, Poster Board #305
  • Serum interleukin 8 (IL-8) may serve as a biomarker of response to Immuno-Oncology therapy
    Author: M. Carleton
    Abstract #3025
    Poster Session: Developmental Therapeutics—Immunotherapy
    Monday, June 4, 8-11:30 AM CDT, Hall A, Poster Board #239
  • Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination Immuno-Oncology therapies (ADVISE), a precision I-O approach to personalized medicine
    Author: J. Luke
    Abstract #TPS3101
    Poster Session: Developmental Therapeutics—Immunotherapy
    Monday, June 4, 8-11:30 AM CDT, Hall A, Poster Board #351a
  • Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer
    Author: I. Melero
    Abstract #TPS3109
    Poster Session: Developmental Therapeutics—Immunotherapy
    Monday, June 4, 8-11:30 AM CDT, Hall A, Poster Board #319a
  • Pharmacodynamics and genomic profiling of patients treated with cabiralizumab plus nivolumab provide evidence of on-target tumor immune modulations and support future clinical applications
    Author: M. Carleton
    Abstract #3020
    Poster Discussion Session: Developmental Therapeutics—Immunotherapy
    Monday, June 4, 8-11:30 AM CDT, Hall A, Poster Board #234
    Discussed at the Poster Discussion Session on Monday, June 4, 11:30 AM-12:45 PM CDT, Hall B1

Head and Neck

  • Nivolumab vs investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Analysis of CheckMate -141 by age
    Author: N. Saba
    Abstract #6028
    Poster Session: Head and Neck Cancer
    Saturday, June 2, 1:15-4:45 PM CDT, Hall A, Poster Board #16

Hematology

  • Extended 5-y follow-up of Phase 3 ELOQUENT-2 study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma
    Author: S. Lonial
    Abstract #8040
    Poster Session: Hematologic Malignancies—Plasma Cell Dyscrasia
    Monday, June 4, 8-11:30 AM CDT, Hall A, Poster Board #49

Genitourinary

  • A Phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (CheckMate -9ER)
    Author: T. Choueiri
    Abstract #TPS4598
    Poster Session: Genitourinary (Nonprostate) Cancer
    Saturday, June 2, 8-11:30 AM CDT, Hall A, Poster Board #418a
  • A Phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care vs SoC alone in patients with previously untreated unresectable or metastatic urothelial carcinoma (CheckMate -901)
    Author: M. Galsky
    Abstract #TPS4588
    Poster Session: Genitourinary (Nonprostate) Cancer
    Saturday, June 2, 8-11:30 AM CDT, Hall A, Poster Board #413a
  • Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate -214 trial
    Author: D. Cella
    Abstract #3073
    Poster Session: Developmental Therapeutics—Immunotherapy
    Monday, June 4, 8-11:30 AM CDT, Hall A, Poster Board #287
  • An open-label, Phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (CheckMate -9KD)
    Author: K. Fizazi
    Abstract #TPS3126
    Poster Session: Developmental Therapeutics—Immunotherapy
    Monday, June 4, 8-11:30 AM CDT, Hall A, Poster Board #327b
  • Efficacy and safety of nivolumab in patients with advanced or recurrent uterine cervical or corpus cancers
    Author: K. Hasegawa
    Abstract #5594
    Poster Session: Gynecologic Cancer
    Monday, June 4, 1:15-4:45 PM CDT, Hall A, Poster Board #321

Lung Cancer

  • Nivolumab plus ipilimumab vs platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Safety analysis and patient-reported outcomes from CheckMate -227
    Author: M. Reck
    Abstract #9020
    Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic
    Sunday, June 3, 8-11:30 AM CDT, Hall A, Poster Board #343
    Discussed at the Poster Discussion Session on Sunday, June 3, 11:30 AM-12:45 PM CDT, Arie Crown Theater
  • Immuno-oncology biomarker study in a large cohort of LC-SCRUM-Japan: Assessment of PD-L1 expression and tumor mutation burden in non-small cell lung cancer patients treated with immune checkpoint inhibitors
    Author: K. Yoh
    Abstract #9070
    Poster Session: Lung Cancer—Non-Small Cell Metastatic
    Sunday, June 3, 8-11:30 AM CDT, Hall A, Poster Board #393
  • Phase 1b trial of nivolumab combined with metformin for refractory/recurrent solid tumors
    Author: T. Kubo
    Abstract #TPS3119
    Poster Session: Developmental Therapeutics—Immunotherapy
    Monday, June 4, 8-11:30 AM CDT, Hall A, Poster Board #324a

Melanoma

  • Treatment-free survival, a novel outcome applied to Immuno-Oncology agents in advanced melanoma
    Author: M. Regan
    Abstract #9531
    Poster Session: Melanoma/Skin Cancers
    Monday, June 4, 1:15-4:15 PM CDT, Hall A, Poster Board #358
  • Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients
    Author: A. Tarhini
    Abstract #9538
    Poster Session: Melanoma/Skin Cancers
    Monday, June 4, 1:15-4:15 PM CDT, Hall A, Poster Board #365
  • Indirect treatment comparison of nivolumab vs placebo as an adjuvant therapy for resected melanoma
    Author: A. Shoushtari
    Abstract #9593
    Poster Session: Melanoma/Skin Cancers
    Monday, June 4, 1:15-4:15 PM CDT, Hall A, Poster Board #420
  • Assessing the value of nivolumab vs placebo and ipilimumab as adjuvant therapy for resected melanoma
    Author: M. Freeman
    Abstract #9594
    Poster Session: Melanoma/Skin Cancers
    Monday, June 4, 1:15-4:15 PM CDT, Hall A, Poster Board #421

Clinical Collaborations

  • Anti-CD27 Agonist antibody varlilumab with nivolumab for colorectal and ovarian cancer: Phase 1/2 clinical trial results
    Author: R. Sanborn
    Abstract #3001
    Oral Abstract Session: Developmental Therapeutics—Immunotherapy
    Saturday, June 2, 3:12-3:24 PM CDT, Hall B1
  • Correlation of degree of tumor immune infiltration and insertion-and-deletion burden with outcome on PD-1 therapy in advanced renal cell cancer
    Author: M. Voss
    Abstract #4518
    Poster Discussion Session: Genitourinary (Nonprostate) Cancer
    Saturday, June 2, 1:15-2:30 PM CDT, Hall D2
    Discussed at the Poster Discussion Session on Saturday, June 2, 1:15-2:30 PM CDT, Hall D2
  • Profiling the immune checkpoint pathway in acute myeloid leukemia
    Author: P. Dama
    Abstract #7015
    Poster Discussion Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
    Monday, June 4, 8-11:30 AM CDT, Hall A, Poster Board #75
    Discussed at the Poster Discussion Session on Monday, June 4, 11:30 AM-12:45 PM CDT, E450
  • Initial results from first-in-human study of IPI-549, a tumor macrophage targeting agent, combined with nivolumab in advanced solid tumors
    Author: R. Sullivan
    Abstract #3013
    Poster Session: Developmental Therapeutics—Immunotherapy
    Monday, June 4, 8-11:30 AM CDT, Hall A
    Discussed at the Poster Discussion Session on Monday, June 4, 11:30 AM-12:45 PM CDT, Hall B1
  • Veliparib in combination with nivolumab and platinum doublet chemotherapy in metastatic/advanced NSCLC
    Author: J. Clarke
    Abstract #3061
    Poster Session: Developmental Therapeutics—Immunotherapy
    Monday, June 4, 8-11:30 AM CDT, Hall A, Poster Board #275
  • Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study
    Author: A. Daud
    Abstract #9511
    Poster Session: Melanoma/Skin Cancers
    Monday, June 4, 1:15-4:15 PM CDT, Hall A, Poster Board #338
    Discussed at the Poster Discussion Session on Monday, June 4, 2018, 4:45-6 PM CDT, E451
  • A Phase 1 study of concomitant galinpepimut-s in combination with nivolumab in patients with WT1+ ovarian cancer in second or third remission
    Author: R. O'Cearbhaill
    Abstract #5553
    Poster Session: Gynecologic Cancer
    Monday, June 4, 1:15-4:45 PM CDT, Hall A, Poster Board #280

Bristol-Myers Squibb & Immuno-Oncology: Advancing Oncology Research

At Bristol-Myers Squibb, patients are at the center of everything we do. Our vision for the future of cancer care is focused on researching and developing transformational medicines, including Immuno-Oncology (I-O) therapeutic approaches, for hard-to-treat cancers that could potentially improve outcomes for these patients.

We are leading the integrated scientific understanding of both tumor cell and immune system pathways, through our extensive portfolio of investigational compounds and approved agents. Our differentiated clinical development program is studying broad patient populations across more than 50 types of cancers with 24 clinical-stage molecules designed to target different immune system pathways. Our deep expertise and innovative clinical trial designs position us to advance the I-O/I-O, I-O/chemotherapy, I-O/targeted therapies and I-O radiation therapies across multiple tumors and potentially deliver the next wave of therapies with a sense of urgency. We also continue to pioneer research that will help facilitate a deeper understanding of the role of immune biomarkers and how a patient’s tumor biology can be used as a guide for treatment decisions throughout their journey.

We understand making the promise of transformational medicines like I-O therapies a reality for the many patients who may benefit from these therapies requires not only innovation on our part but also close collaboration with leading experts in the field. Our partnerships with academia, government, advocacy and biotech companies support our collective goal of providing new treatment options to advance the standards of clinical practice.

About Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Opdivo’s leading global development program is based on Bristol-Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has enrolled more than 25,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 60 countries, including the United States, the European Union and Japan. In October 2015, the company’s Opdivo and Yervoy combination regimen was the first Immuno-Oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries, including the United States and the European Union.

INDICATIONS

OPDIVO® (nivolumab) as a single agent is indicated for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

OPDIVO® (nivolumab) as a single agent is indicated for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of patients with metastatic non small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

OPDIVO® (nivolumab) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with intermediate or poor-risk, previously untreated advanced renal cell carcinoma (RCC).

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or more lines of systemic therapy that includes autologous HSCT. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.

OPDIVO® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

OPDIVO® (nivolumab) is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

OPDIVO® (10 mg/mL) is an injection for intravenous (IV) use.

IMPORTANT SAFETY INFORMATION

WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS

YERVOY can result in severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy. The majority of these immune-mediated reactions initially manifested during treatment; however, a minority occurred weeks to months after discontinuation of YERVOY.

Assess patients for signs and symptoms of enterocolitis, dermatitis, neuropathy, and endocrinopathy and evaluate clinical chemistries including liver function tests (LFTs), adrenocorticotropic hormone (ACTH) level, and thyroid function tests at baseline and before each dose.

Permanently discontinue YERVOY and initiate systemic high-dose corticosteroid therapy for severe immune-mediated reactions.

Immune-Mediated Pneumonitis

OPDIVO can cause immune-mediated pneumonitis. Fatal cases have been reported. Monitor patients for signs with radiographic imaging and for symptoms of pneumonitis. Administer corticosteroids for Grade 2 or more severe pneumonitis. Permanently discontinue for Grade 3 or 4 and withhold until resolution for Grade 2. In patients receiving OPDIVO monotherapy, fatal cases of immune-mediated pneumonitis have occurred. Immune-mediated pneumonitis occurred in 3.1% (61/1994) of patients. In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg, immune-mediated pneumonitis occurred in 6% (25/407) of patients. In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg, immune-mediated pneumonitis occurred in 4.4% (24/547) of patients.

In Checkmate 205 and 039, pneumonitis, including interstitial lung disease, occurred in 6.0% (16/266) of patients receiving OPDIVO. Immune-mediated pneumonitis occurred in 4.9% (13/266) of patients receiving OPDIVO: Grade 3 (n=1) and Grade 2 (n=12).

Immune-Mediated Colitis

OPDIVO can cause immune-mediated colitis. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 (of more than 5 days duration), 3, or 4 colitis. Withhold OPDIVO monotherapy for Grade 2 or 3 and permanently discontinue for Grade 4 or recurrent colitis upon re-initiation of OPDIVO. When administered with YERVOY, withhold OPDIVO and YERVOY for Grade 2 and permanently discontinue for Grade 3 or 4 or recurrent colitis. In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients. In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg, immune-mediated colitis occurred in 26% (107/407) of patients including three fatal cases. In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg, immune-mediated colitis occurred in 10% (52/547) of patients.

In a separate Phase 3 study of YERVOY 3 mg/kg, severe, life-threatening, or fatal (diarrhea of ?7 stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) patients. Across all YERVOY-treated patients in that study (n=511), 5 (1%) developed intestinal perforation, 4 (0.8%) died as a result of complications, and 26 (5%) were hospitalized for severe enterocolitis.

Immune-Mediated Hepatitis

OPDIVO can cause immune-mediated hepatitis. Monitor patients for abnormal liver tests prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater transaminase elevations. For patients without HCC, withhold OPDIVO for Grade 2 and permanently discontinue OPDIVO for Grade 3 or 4. For patients with HCC, withhold OPDIVO and administer corticosteroids if AST/ALT is within normal limits at baseline and increases to >3 and up to 5 times the upper limit of normal (ULN), if AST/ALT is >1 and up to 3 times ULN at baseline and increases to >5 and up to 10 times the ULN, and if AST/ALT is >3 and up to 5 times ULN at baseline and increases to >8 and up to 10 times the ULN. Permanently discontinue OPDIVO and administer corticosteroids if AST or ALT increases to >10 times the ULN or total bilirubin increases >3 times the ULN. In patients receiving OPDIVO monotherapy, immune-mediated hepatitis occurred in 1.8% (35/1994) of patients. In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg, immune-mediated hepatitis occurred in 13% (51/407) of patients. In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg, immune-mediated hepatitis occurred in 7% (38/547) of patients.

In Checkmate 040, immune-mediated hepatitis requiring systemic corticosteroids occurred in 5% (8/154) of patients receiving OPDIVO.

In a separate Phase 3 study of YERVOY 3 mg/kg, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations >5x the ULN or total bilirubin elevations >3x the ULN; Grade 3-5) occurred in 8 (2%) patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4%.

Immune-Mediated Neuropathies

In a separate Phase 3 study of YERVOY 3 mg/kg, 1 case of fatal Guillain-Barré syndrome and 1 case of severe (Grade 3) peripheral motor neuropathy were reported.


Contacts

Bristol-Myers Squibb
Media:
Audrey Abernathy, 919-605-4521
[email protected]
or
Investors:
Tim Power, 609-252-7509
[email protected]
or
Bill Szablewski, 609-252-5894
[email protected]


Read full story here

Page: 1


Related Keywords:

-->

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved